Market Place
Sourcing Support
Bicara Therapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Bicara Therapeutics to Present at Stifel 2024 Healthcare Conference
11 Nov 2024 //
GLOBENEWSWIRE
Upstream Bio, two other US biotech startups price IPOs
11 Oct 2024 //
REUTERS
Mazumdar-Shaw’s niece makes debut at Nasdaq as Bicara goes public
27 Sep 2024 //
FINANCIALXPRESS
Bicara Therapeutics Closes $362 Million Initial Public Offering
16 Sep 2024 //
GLOBENEWSWIRE
TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut
13 Sep 2024 //
REUTERS
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering
12 Sep 2024 //
GLOBENEWSWIRE
TPG-backed Bicara Therapeutics raises $315 mln in US IPO
12 Sep 2024 //
REUTERS
Bicara Therapeutics targets $265 mln proceeds in upsized US IPO
11 Sep 2024 //
REUTERS
Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO
06 Sep 2024 //
REUTERS
Bicara Expands Board With Appointments Of Mike Powell And Christopher Bowden
15 Aug 2024 //
BUSINESSWIRE
Bicara Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101)
27 Jun 2024 //
BUSINESSWIRE
Bicara Expands Clinical Team with Appointments of Schulten and Rita Dala
26 Mar 2024 //
BUSINESSWIRE
Bicara Therapeutics to Participate in Upcoming March Investor Conferences
27 Feb 2024 //
BUSINESSWIRE
Bicara to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
Bicara Therapeutics Appoints Lara Meisner as Chief Legal Officer
18 Dec 2023 //
BUSINESSWIRE
Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing
12 Dec 2023 //
BUSINESSWIRE
Bicara secures its second nine-figure financing of the year
12 Dec 2023 //
ENDPTS
Bicara raises second $100M+ round of 2023, closing new series C
12 Dec 2023 //
FIERCE BIOTECH
Bicara Therapeutics to Present at Upcoming November Investor Conferences
08 Nov 2023 //
BUSINESSWIRE
Bicara Therapeutics Presents Interim Data from Phase 1/1b Study of BCA101
23 Oct 2023 //
BUSINESSWIRE
Bicara Therapeutics Appointed Kate Haviland and Scott Robertson
16 Oct 2023 //
BUSINESSWIRE
Bicara Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
24 Jul 2023 //
BUSINESSWIRE
Bicara’s BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab
05 Jun 2023 //
BUSINESSWIRE
Data show Bicara’s bispecific helps shrink head when combined with Keytruda
05 Jun 2023 //
ENDPTS
Bicara Therapeutics to Present at 2023 Jefferies Global Healthcare Conference
01 Jun 2023 //
BUSINESSWIRE
Bicara Therapeutics to Present Preclinical Data from BCA101, at AACR
04 Apr 2023 //
BUSINESSWIRE
Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing
06 Mar 2023 //
BUSINESSWIRE
Bicara Therapeutics to Present at Annual Piper Sandler Healthcare Conference
22 Nov 2022 //
BUSINESSWIRE
Bicara Therapeutics Presents Preclinical Data for Precision Immunocytokine
07 Nov 2022 //
BUSINESSWIRE
Bicara Tx Presents Data from Dose Escalation Portion of Ongoing PI/Ib of BCA101
03 Jun 2022 //
BUSINESSWIRE
Bicara Initiates Dose Expansion Arm of Phase 1/1b Clinical Study of BCA101
22 Feb 2022 //
BUSINESSWIRE
Bicara Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
06 Jan 2022 //
BUSINESSWIRE
Bicara to Present Clinical Data from Lead Immunotherapy Program, BCA101
18 May 2021 //
WBOC
